The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Kasatkin D.S.
Yaroslavl State Medical University
Korobko D.S.
State Novosibirsk Regional Clinical Hospital;
Novosibirsk State Medical University
Matson M.D.
Tula Regional Clinical Hospital
Lendoeva D.V.
Yaroslavl State Medical University
Ivanova S.P.
Lipetsk Regional Clinical Hospital
Approaches to vaccine prevention in multiple sclerosis
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(9): 29‑36
Read: 4485 times
To cite this article:
Kasatkin DS, Korobko DS, Matson MD, Lendoeva DV, Ivanova SP. Approaches to vaccine prevention in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry.
2022;122(9):29‑36. (In Russ.)
https://doi.org/10.17116/jnevro202212209129
The article presents an overview of modern approaches to vaccine prevention in multiple sclerosis (MS). Compared with the general population, patients with MS have been shown to have an increased risk of morbidity, a tendency to have a more severe course, and a greater mortality from vaccine-preventable infections. At the same time, in Russia, until recently, traditionally adhered to a conservative tactic of limiting vaccination in patients with autoimmune diseases, including MS. The use of various disease-modifying therapies (DMT) may also affect the susceptibility to infections and the severity of their course. Screening for latent infections, determination of immune status, collection of history of past infections and development of a vaccination plan based on these data are an important part of the preparation before the appointment of DMT to control the occurrence or reactivation of infections. The use of inactivated, subunit, conjugate, and toxoid-based vaccines are preferable for MS patients. When developing a vaccination plan, avoid live-attenuated vaccines whenever possible. There are no restrictions on vaccination during first line DMT intake. In case of vaccination in MS patients while using immunosuppressants, including drugs for immune reconstitution therapy, an individual risk assessment and timing are required. The available data on the awareness of patients about vaccine prophylaxis are significantly limited and require mass information events.
Authors:
Kasatkin D.S.
Yaroslavl State Medical University
Korobko D.S.
State Novosibirsk Regional Clinical Hospital;
Novosibirsk State Medical University
Matson M.D.
Tula Regional Clinical Hospital
Lendoeva D.V.
Yaroslavl State Medical University
Ivanova S.P.
Lipetsk Regional Clinical Hospital
Received:
23.08.2022
Accepted:
01.09.2022
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.